Once so valuable its market capitalization eclipsed that of its home country of Denmark, pharmaceutical giant Novo Nordisk is now showing signs of strain. Most recently, several members of Novo Nordisk’s board of directors quit after failing to reach an agreement with the Novo Nordisk Foundation, the firm’s controlling shareholder (via Novo Holdings), on the…
Tirzepatide cut sleep apnea index by up to 63% in phase 3 trials
Today, Lilly announced promising data for the SURMOUNT-OSA phase 3 clinical trials testing tirzepatide in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. The company shared the data at the American Diabetes Association’s (ADA) 84th Scientific Sessions while publishing them in The New England Journal of Medicine (NEJM). The SURMOUNT-OSA phase 3 trial consists…